Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical company Zogenix (Nasdaq: ZGNX) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Zogenix's business and see what CAPS investors are saying about the stock right now.

Zogenix facts

Headquarters (founded) San Diego (2006)
Market Cap $234.5 million
Industry Pharmaceuticals
Trailing-12-Month Revenue $44.7 million
Management CEO Roger Hawley
Co-Founder/COO Dr. Stephen Farr
Trailing-12-Month Return on Capital (139.3%)
Cash/Debt $22.0 million / $52.4 million
Competitors AstraZeneca

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 38% of the 47 members who have rated Zogenix believe the stock will underperform the S&P 500 going forward.

Earlier this week, one of those Fools, All-Star zzlangerhans, succinctly summed up the Zogenix bear case for our community:

There's clearly a committed base following of this stock, since the share price is rising despite predictably weak and declining revenues from Sumavel DosePro and a nasty 47.5M share dilutive financing (warrants with a below market strike might as well be shares). Who's that white knight on the horizon? None other than Zohydro, yet another superfluous oral opiate tablet that will fail to take market share from generic hydrocodone and oxycodone. I don't think I'll have to wait until the rundown after the PDUFA next March to close this pick.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.